Shangping Fang

Dr. Shangping Fang

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2024
Verified
Journal Article
Closed access
SFShangping Fang
Shangping Fang
RSR Sun
R Sun
HSH Su
H Su
KZK Zhai
K Zhai
YXY Xiang
Y Xiang
WGW Guo
W Guo

20 August 2025
Verified
Journal Article
Closed access
SFShangping Fang
Shangping Fang
JLJiameng Liu
Jiameng Liu
XYXingchen Yue
Xingchen Yue
HLHuan Li
Huan Li
WLWanning Li
Wanning Li
PBPengju Bao
Pengju Bao

31 December 2025 in Perioperative Precision Medicine
Verified
Journal Article
Closed access
HLHuan Li
Huan Li
XTXiaoyu Tang
Xiaoyu Tang
JLJiameng Liu
Jiameng Liu
WLWanning Li
Wanning Li
XNXin Niu
Xin Niu
SFShangping Fang
Shangping Fang
Acute liver failure (ALF) is a severe hepatic injury characterized by rapid progression and multifactorial etiology. Clinical manifestations predominantly include severe gastrointestinal symptoms, altered consciousness, coagulopathy, jaundice, and hepatic encephalopathy. Currently, no specific pharmacological agents or established therapeutic regimens exist for ALF. While liver transplantation remains the primary clinical intervention, its application is limited by the shortage of donors. Advances in medical technology and research have led to accumulating experimental evidence suggesting that mesenchymal stem cells (MSCs) can alleviate liver inflammation, improve hepatic histology and function, and enhance survival rates in ALF. MSCs have advanced to clinical trials, with ongoing exploration into the mechanisms underlying their efficacy, highlighting their substantial potential in regenerative medicine. In the future, BM-MSCs may become an important treatment option for patients with acute liver failure during the perioperative period. This review provides a comprehensive overview of the therapeutic mechanisms and key findings associated with stem cells, particularly BM-MSCs, in the treatment of ALF.